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Supplementary Information 
Supplementary Figure Legends 
Supplementary Figure 1. LPS-mediated IFNβ  and ISG54 mRNA expression is attenuated in 
hDCs upon TRIM6 silencing, related to Figure 1. (A) Representation of the TLR4, RIG-I and 
MDA5 signaling pathways investigated. (B) Monocyte-derived hDCs transduced with 
lentiviruses expressing TRIM6-specific shRNAs were stimulated with LPS. (C-E) Each condition 
was repeated in three different donors. At 2 h post treatment, cells were harvested and their 
TRIM6, IFNβ, ISG54, TNFα, IL-6 and IL-8 mRNA levels determined by RT-qPCR and plotted 
as percentage of control or fold induction over mock-induced samples, as indicated.  
Supplementary Figure 2. Specific TRIM6 silencing reduces IFNβ  production upon poly I:C 
stimulation, related to Figure 2. A549 cells were transiently tranfected with a non-targeting 
control or TRIM6-specific siRNAs. Forty h p.t., cells were either mock-treated or stimulated with 
poly I:C for 24 h. (A) Mock-treated cells were harvested for RT-qPCR analysis of TRIM6, 
TRIM1, TRIM5, TRIM13, TRIM25 mRNA to confirm specific silencing. (C) Suppernatants 
from stimulated cells were collected for IFNβ ELISA. (B) HEK-293T cells were transiently 
tranfected with a non-targeting control or TRIM6-specific targeting siRNA sequence. Silencing 
efficiency was confirmed by IB.  
Supplementary Figure 3. IKKε interacts with TRIM6 in vitro and co-localize in hDCs, 
related to Figure 3. (A) Monocyte-derived human DCs mock-treated or stimulated with IFNβ 
for 45 minutes or 6 hr or infected with SeV for 6 hr were fixed and stained with anti-TRIM6 
(red), anti-IKKε (green) and DAPI (nucleus, blue). Co-localization was determined by confocal 
microscopy. (B) In vitro binding assay. Baculovirus-produced recombinant FLAG-IKKε protein 
was incubated with GST-TRIM6-RBCC or GST-TRIM6-SPRY in vitro followed by 
immunoprecipitation with anti-FLAG beads.  
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Supplementary Figure 4. TRIM6 silencing enhances expression of IFNγ-inducible genes and 
IFNβ  does not activate TBK1 phosphorylation, related to Figure 4. 
(A) A549 cells were transiently tranfected with a non-targeting control or TRIM6-specific 
targeting siRNA sequence. Forty h p.t., cells were mock-treated or stimulated with IFNγ (500 
U/ml). Cells were harvested at the indicated time points for RT-qPCR analysis. (B) hDCs 
transduced with lentiviruses expressing TRIM6 shRNAs were stimulated with IFNβ (100U/ml) 
and subjected to IB analysis. 
Supplementary Figure 5. IKKε interacts with K48-linked poly-ubiquitin chains synthesized 
by TRIM6 in the lungs of influenza virus infected mice in vivo, related to Figure 5. 
(A) Western blot analysis of TRIM6 silencing in MEFs using peptide-conjugated 
phosphorodiamidate morpholino oligomers (PPMO). (B) Schematic representation of in vivo 
experiments. BALB/c mice were infected i.n. with influenza A virus PR8 strain (1000 PFU). 
Lungs were collected at the indicated time points p.i. Half of each lung was used to determine (C) 
viral load by plaque assay and (E) IP of IKKε followed by IB with indicated antibodies. (D) The 
other half of the lung was used for RT-qPCR analysis for influenza A virus M1, IFNβ, TRIM6 
and IFN inducible gene ADAR1 mRNA levels. (F) Schematic representation of TRIM6 silencing 
in vivo. BALB/c mice were treated with TRIM6-targeting PPMO, non-targeting control PPMO or 
vehicle only (PBS) (day -2). This treatment was repeated 24 hr later (day -1) followed by 
influenza PR8 infection (1000 PFU) (day 0). At indicated time points p.i. lungs were collected for 
RT-qPCR (G). Results are from a single experiment (n = 3 for influenza A virus infected 
samples) and error bars indicate SD.  *p < 0.05; **p < 0.01; ***p < 0.001 by T-test. (H) Lanes 
from the immunoblot shown in Figure 5H for IP with the samples of the PPMO treated mice were 
quantified using ImageJ and normalized to the lowest value within each individual blot 
(arbitrarily set to 1). Results were plotted as bar graphs.  
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Supplementary Figure 6. IKKε interacts with K48-linked unanchored polyubiquitin chains 
in cell-culture, in vivo and in vitro, related to Figure 6 
(A) Schematic overview of the denaturing pulldown assay. (B) Schematic overview of the assay 
for unanchored polyubiquitin chains using isopeptidase T/USP5 (IsoT), which specifically 
degrades unanchored Ub through recognition of its exposed C-terminal diglycine residues, while 
not deconjugating attached Ub chains.  (C) WCE of HEK-293T cells, transfected with FLAG-
IKKε plasmid together HA-TRIM6 were subjected to FLAG-IP. The beads which contained poly-
ubiquitin chains bound to FLAG-IKKε were incubated with or without IsoT for 1 hr at 30°C and 
analyzed by IB. (D) WT or Ifnar1-/- mice were infected i.n. with influenza A virus PR8 strain 
(1000 PFU). Lungs were collected at the indicated time points, lysed, and subjected to IP with 
anti-IKKε or isotype control antibody. The beads containing poly-ubiquitin chains bound to IKKε 
from samples at day 3 p.i. were incubated with IsoT for 1hr at 30°C (last 2 lanes). Samples were 
analyzed by IB with indicated antibodies. (E) In vitro binding assay with ubiquitin chains. 
Baculovirus-produced recombinant FLAG-IKKε protein was incubated for 2 hr at 4°C with K48 
or K63-linked poly-ubiquitin chains (2-7 Ub/chain), K48-linked poly-ubiquitin chains 2-16 
Ub/chain, or tetra-ubiqutin with mixed linkages (K48-K643), followed by immunoprecipitation 
with anti-FLAG beads.  (F) Formation of TRIM6 cytoplasmic bodies, but not colocalization  with 
IKKε requires unanchored poly-ubiquitin chains. At 24 h p.t. with HA-TRIM6, FLAG-IKKε and 
His-IsoT, HeLa cells were stained with anti-His (green), anti-FLAG (red), anti-HA (violet) and 
DAPI (nucleus, blue). (G) WCE of HEK-293T cells, transfected with HA-TRIM6 or V5-TRIM25 
were subjected to HA or V5 IP respectively. The beads containing HA-TRIM6 or V5-TRIM25 
were incubated with or without IsoT for 1hr at 30°C and analyzed by IB. 
Supplementary Figure 7. K48-linked poly-ubiqitin chains interact with the kinase domain 
of IKKε, promoting its oligomerization and activation. related to Figure 7. 
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(A) Purified FLAG-IKKε or a kinase-dead FLAG-IKKε mutant (K38A) were incubated with 
recombinant E1, UbE2K, and TRIM6 with mono-ubiquitin WT, K48R mutant or K48only 
mutant, in the presence of ATP.  After 1 h incubation at 30°C, the reaction mixture was subjected 
to IB with the indicated antibodies. (B) Endogenous unanchored poly-Ub chains induce IKKε-
mediated STAT1 phosphorylation. Schematic representation of the assay. (C) Schematic 
representations of the FLAG-IKKε deletion mutants used for CoIP. (D) WCE of HEK-293T cells 
transfected with FLAG-IKKε WT or FLAG-IKKε truncations or a FLAG-IKKε S172A mutant 
(transactivation loop) together with HA-TRIM6, were subjected to IP with anti-FLAG beads, 
followed by IB. (E-F) HEK-293T cells were transfected with ISG54 luciferase reporter plasmid 
together with empty vector, and increasing concentrations of FLAG-IKKε WT or FLAG-IKKε 
S172A (E), and in the presence of TRIM6 (F). At 24 h p.i., cells were lysed and subjected to 
luciferase assay. (G) IKKε oligomerization assay. Purified FLAG- IKKε protein was incubated 
with increasing amounts of K48-linked ubiquitin chains (2-7) in the absence of ATP (left panel) 
or with K48-linked ubiquitin chains (2-7 and 2-16 ub/chain) in presence of ATP (right panel) at 
37°C for 15 minutes to allow formation of complexes, followed by native PAGE and IB using 
anti-FLAG antibody. RIG-I-YFP, which runs at 130 Kd, was used as a control of molecular 
weight. (H) TRIM6 interacts with JAK1 kinase. WCE of HEK-293T cells, that had been 
transfected with FLAG-JAK1 together with empty vector or HA-TRIM6 were subjected to IP 
with anti-FLAG beads (left panel) or anti-HA beads (right panel) and analysed by IB with 
indicated antibodies. Potential TRIM6 phorsphorylated bands oberved in the presence of JAK1  
are indicated with arrows in the right panel. (I) WCE of HEK-293T cells transfected with FLAG-
JAK1 or HA-TRIM6 were subjected to IP with anti-HA beads and analysed by IB with an anti-
phospho-tyrosine or the indicated antibodies. (J) Proposed model of IKKε activation: TRIM6 and 
UbE2K cooperate in the synthesis of K48-linked unanchored poly-Ub chains, which activate 
IKKε for STAT1 phosphorylation and induction of a subset ISGs required for the antiviral 
response. 
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Supplemental Experimental procedures 
Cell culture and Transfection  
HEK-293T, HeLa and A549 were purchased from ATCC. Ikbke+/+ and Ikbke -/- (IKKε knockout) 
MEFs were previously described (Tenoever et al., 2007). All cells were maintained in Dulbecco's 
Modified Eagle's Medium (DMEM) supplemented with 10% fetal bovine serum (FBS), 2 mM L-
glutamine and 1% penicillin-streptomycin (Gibco-BRL). Transient transfections were performed 
with TransIT-LT1 (Mirus) or Lipofectamine 2000 (Invitrogen) according to the manufacturer’s 
instructions.  
Plasmids 
Reporter plasmids expressing firefly luciferase under the control of the ISG54-ISRE, NF-κB, and 
the IFNβ promoter were described previously (Kochs et al., 2007; Yoneyama et al., 1998). 
FLAG-tagged RIG-I(2CARD) was previously described (Nistal-Villan et al., 2010). The reporter 
plasmid carrying the Renilla luciferase gene (REN-Luc/pRL-TK) was purchased from Promega. 
The HA-TRIM6 plasmid was kindly provided by Andrea Ballabio (Reymond et al., 2001). 
TRIM6 mutants were generated by mutagenesis PCR and cloned in-frame with the HA-tag 
sequence into the pCAGGS-HA expression plasmid using KpnI and XhoI restriction sites. All 
sequences were confirmed by sequencing analysis (Genewiz, NJ). 
 
Viruses 
Sendai virus (SeV; Cantell strain) was obtained from Charles River Laboratories. Influenza 
A/Puerto Rico/8/1934 virus (PR8) virus titers were determined by plaque assay using MDCK 
cells. The PR8-GFP virus was described previously (Manicassamy et al., 2010). 
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IFNβ, NF-kB and ISG54 Luciferase Reporter Assay 
HEK-293T cells were transfected in 24-well plates (Falcon, Becton Dickinson, NJ) with 50 ng of 
IFNβ, NF-kB or ISG54 reporter plasmid together with 20 ng of Renilla luciferase, 0.2-1 ng of 
stimulating plasmid (RIG-I[2CARD], IKKε, TBK-1) and 1-20ng of TRIM6 plasmid. Empty 
pCAGGs plasmid was used to bring the total amount of plasmid to 100ng/well. Plasmids were 
transfected using TransIT-LT1 (Mirus) at a ratio of 1:3. 30 h p.t., cells were lysed and a dual-
luciferase assay was performed according to the manufacturer's instructions (Promega). Values 
were normalized to Renilla, and the fold induction was calculated as the ratio of stimulated 
samples, or samples transfected with inducing plasmid versus samples transfected with empty 
plasmid (no stimulation). WT and Ikbke -/- MEFs were transfected using Lipofectamine 2000 at a 
ratio 1:2.  
 
Screen for E2 ubiquitin ligases 
HA-TRIM6 was immuno-purified from HEK-293T cells using HA-beads and eluted with HA 
peptide. To determine the E2 ubiquitin ligase that cooperates with TRIM6 for synthesis of 
ubiquitin chains, E2 SCAN kit was used according to the manufacturer's instructions (Ubiquigent, 
Cambridge, USA).  In brief, E1 enzyme UbE1, ubiquitination buffer, ubiquitin and 0.5 µl 
immuno-purified HA-TRIM6 protein were mixed and added to a 96-well plate containing each of 
the 29 E2 enzymes as described by the manufacturer. The reaction was initiated with the addition 
of ATP and incubated for  1h at 30°C. The reaction was stopped  by addition of Laemmli sample 
buffer (BioRad) containing β-Mercaproethanol, and boiled for 5 min. The poly-ubiquitin was 
detected by western blot using anti-ubiquitin antibody. 
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Isolation and analysis of endogenous poly-ubiquitin chains 
We followed a previously described protocol to isolate chains from RIG-I(2CARD) used by Zeng 
et.al. (Zeng et al., 2010). In brief, HEK-293T cells were transfected in 10cm dishes with 5µg of 
FLAG-IKKε plasmid alone or together with TRIM6. Cells were lysed in IP buffer, supplemented 
with 10mM N-ethylmaleimide (NEM) (Sigma). After centrifugation at 15,000xg, 5mM DTT was 
added to quench the NEM. FLAG-IKKε was isolated using FLAG M2 affinity gel (Sigma). The 
beads containing IKKε were incubated at 75°C/5 min. After centrifugation, the supernatant 
containing the poly-ubiquitin chains was used for in vitro kinase assay.  For deubiquitinating 
enzyme treatment, the supernatants containing the dissociated poly-ubiquitin were incubated with 
200nM of Isopeptidase T/USP5 (IsoT) (Boston Biochem) for 1h/30°C. These treated supernatants 
were used for in vitro kinase assay. 
 
Confocal Microscopy  
HeLa cells or hDCs were seeded into Lab-Tek II 8-well chamber slides (CC2 Glass slide, Nunc). 
After 12-16 h, plasmids harboring HA or GST-tagged TRIM6, FLAG-IKKε, and ubiquitin (His, 
FLAG or HA tagged)  plasmids were transfected with Lipofectamine 2000 (Invitrogen) at a ratio 
1:1. Six h p.t. the medium was changed. Twenty-four h later, cells were washed with PBS, fixed 
with methanol-acetone (1:1), permeabilized with 0.5% NP-40 (v/v) in PBS, and blocked with 
0.5% BSA and 0.2% fish gelatin in PBS. For triple stains, cells were stained with directly 
conjugated mouse monoclonals anti-HA (Alexa Fluor 488 or 647, Cell Signaling), anti-FLAG 
(Alexa Fluor 555, Cell Signaling), anti-His (Alexa Fluor 488, Millipore), or anti-GST (Alexa 
Fluor 647, Cell Signaling) as well as DAPI (Invitrogen). For double stains, secondary anti-mouse 
or anti-rabbit antibodies conjugated to Alexa-fluor 488 and Alexa-fluor 555 (Invitrogen), 
respectively, were used to visualize the proteins. Images were taken on a Leica SP5 DM confocal 
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microscope (Leica Microsystems) at a magnification of 63x. Confocal laser scanning microscopy 
was performed at the MSSM-Microscopy Shared Resource Facility. 
 
Electrophoretic mobility shift assay (EMSA) 
Binding assays were performed with whole cell extracts in NP-40 lysis buffer (1% Nonidet P40, 
50mM Tris pH 7.4, 5mM ETDA, 30mM NaF, 10% glycerol, supplemented with 1mM PMSF and 
protease inhibitor cocktail (Roche)). 50µg of protein extract were normalized in 10mM HEPES 
pH7.9, 2% glycerol, 40mM KCl, 1mM EDTA, 0.2mM MgCl2, and 1mM DTT in a total volume 
of less than 15µl. 1µg of poly(dI:dC) (Sigma) was added to each sample to eliminate non-specific 
binding and the reaction was incubated on ice for 10min. 100000-300000 CPU of labeled probe 
was added and incubated at room temperature for 20min. Samples were resolved on a 6% native 
acrylamide gel. Gels were dried and exposed by autoradiogram. Probe sequences:              
MxA:  CCGCGCCGCGAAGAAATGAAACTCACA 
OAS1: CCTTCTGAGGAAACGAAACCAACAGCA 
ISG15: CTCGGGAAAGGGAAACCGAAACTGAAG 
 
In vitro STAT1 kinase assay  
GST-tagged murine STAT1 (aminoacids 609-749) was purified from XL1blue bacteria and 
FLAG-tagged IKKε was isolated from HEK-293T with anti-FLAG beads. 0.1µl of purified Flag-
tagged IKKε was incubated for 1h at 4˚C in 20mM Hepes pH7.5 and 10% glycerol with 
increasing amounts (14, 100, or 700 ng/µl) of commercial recombinant ubiquitin chains (Boston 
Biochem or K48-linked 2-16 from Millipore) or endogenous chains isolated as described above. 
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Subsequently, 5µg of GST-STAT1 and 1µl of [gamma 32P]-ATP (3000Ci/mmol) were added and 
the kinase reaction was incubated for 30min at 30˚C in kinase buffer (25 mM Tris HCl, pH 7.5, 
10mM MgCl2, 5mM glycerophosphate, 2mM DTT, 1mM Na3VO4). The reaction was analysed 
by SDS-PAGE and visualized by Coomassie staining or auto-radiography. Baculovirus produced 
recombinant IKKε was purified as previously described (Tenoever et al., 2007). 
 
Production of lentivirus VLPs for TRIM6 knockdowns 
SIV VLPs were produced by Fugene6 (Roche) mediated co-transfection of HEK-293T cells with 
minigenome plasmid pSIV3+ and VSV-G envelope vector pHCMV-VSVG in a ratio of 5:1. 
Lentiviruses expressing anti-TRIM6 shRNAs were produced by transfecting HEK-293T cells 
with HIV gag-pol plasmid pCRV1-gag-pol, mini-genome plasmids harboring TRIM6-specific 
shRNA sequences (Santa Cruz biotechnology) and VSV-G envelope plasmid vector  pHCMV-
VSVG in a ratio of 5:5:1. At 48-72 h p.t. supernatants were collected, cleared by low-speed 
centrifugation and purified over a 20% sucrose cushion as previously described. Virus stocks 
were titered by exo-RT activity (EnzCheck, Invitrogen). A GFP expressing control virus was 
routinely produced, which was in addition tittered by TCID50 on 293T cells and hDCs in the 
presence of SIV VLPs. The lowest amount of SIV and GFP lentivirus required to transduce >95% 
of hDCs by FACS was used for transduction with anti-TRIM shRNA expressing lentiviruses 
produced together with the GFP control virus. 
 
Isolation and differentiation of human DCs 
Peripheral blood mononuclear cells were isolated from buffy coats of healthy human donors by 
Ficoll density gradient centrifugation. Buffy coats were obtained from the Mount Sinai Blood 
Donor Center and New York Blood Center. In brief, CD14+ cells were purified using anti-human 
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CD14 antibody-labeled magnetic beads and iron-based MiniMACS LS columns (Miltenyi 
Biotech). After elution from the columns, 2 x 105 cells were plated in 96-well plates in DC 
medium (RPMI medium [Invitrogen], 10% fetal calf serum [HyClone, Thermo Scientific], 2 mM 
L-glutamine, 1 mM sodium pyruvate, 50 µg/ml gentamycin, 100 U/ml penicillin, and 100 µg/ml 
streptomycin [Gibco, Invitrogen]) supplemented with 500 U/ml human granulocyte-macrophage 
colony-stimulating factor (hGM-CSF; Peprotech), and 1,000 U/ml human interleukin-4 (hIL-4; 
Peprotech). 
TRIM6 knockdown in human DCs with shRNA lenti-viral vectors 
Freshly isolated monocytes were transduced with VSV-G pseudo-typed SIV VLPs and shRNA 
plasmid containing VLPs for 3 h by spinoculation in the presence of 2 µg/mL polybrene (Sigma). 
Equal amounts of each virus were added, just sufficient to transduce >95% of the cells. Each 
condition was represented by two (donor 3 and 4) or four (donor 1 and 2) replicate wells. 
Subsequently, cells were washed, resuspended in DC medium supplemented with hGM-CSF and 
hIL-4, and incubated for 5 days at 37°C until stimulation. At 5 d post-transduction, hDCs were 
either induced with a final concentration of 0.4 ng/mL LPS (Alexis Biochemicals; 581-008-L002) 
or IFNβ 1000 U/ml. 
 
siRNA-mediated knockdown 
Transient knockdown of endogenous TRIM6 in A549 or HEK-293T cells, seeded in 24-well 
plates (30,000 cell/well), was achieved by transfection of 10 picomol of non-targeting (scramble) 
control or siRNA specific for TRIM6 (Invitrogen/Life technologies, sleath RNAi TRIM6-specific 
sequence targeting the 5’-UTR region of transcript variant 2; sense: 
GCUGCUUCAAGUCCUUGGCUCUGAU and antisense: 
AUCAGAGCCAAGGACUUGAAGCAGC). The RNAi was transfected with RNAiMAX 
(Invitrogen) according to the manufacturer’s instructions. After 24 h, cells were transfected again 
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with the same siRNA amounts. After 6-8 h medium was replaced with fresh medium and cells 
were left for additional 12 h. TRIM6 knockdown efficiency was determined by qPCR using 
specific primers, and by IB with a specific TRIM6 antibody (Ab1, Sigma). For viral infections, 
cells were infected with SeV (10 HAU/ml) or PR8 influenza (MOI=2) viruses for the indicated 
time points. Cells were then harvested for qPCR or IB. 
 
GST pull-down assay, immunoprecipitation, and immunoblot analysis  
HEK-293T and human DCs were lysed in IP buffer (50 mM TRIS, pH8.0, 280 mM NaCl, 0.5% 
[v/v] NP40, Glycerol 10%, protease inhibitor cocktail [Roche], 10mM N-ethylmaleimide (NEM). 
GST pull-down and immunoprecipitations were performed using Glutathione Sepharose 4B (GE 
Healthcare), anti-FLAG M2 affinity gel (Sigma), mouse monoclonal anti-human IKKε (Abcam) 
or mouse monoclonal anti-mouse IKKε (Imgenex). Its important to note that for the 
ubiquitination assays in which IKKε and TRIM6 were co-expressed together, a very low amount 
of IKKε was used (and the amount of TRIM6 was carefully determined in titration experiments). 
Normally, about 400,000 HEK-293T cells were trasfected using TransIT-LT1 (Mirus) with 4ng 
of Flag-IKKε together with 50-200ng of HA-TRIM6 (or GST-TRIM6 as indicated) in 6 well 
plates.    
For immunoblotting, proteins were resolved by SDS-polyacrylamide gel electrophoresis (SDS-
PAGE) and transferred onto a PVDF membrane (Immobilon-P, Millipore). The following 
primary antibodies were used: anti-FLAG (Rabbit,Sigma), anti-HA (Rabbit, Sigma), anti-GST 
(Rabbit) (Sigma), anti-β-actin (Abcam), anti-human IKKε (Rabbit, Abcam), anti-phosphoIKKε 
T500 Rabbit, Novus Biologicals), anti-TRIM6 (Rabbit, Ab1, Sigma), anti-phosphoIRF3 (S386) 
(rabbit, Epitomics), anti-ubiquitin K48-specific (Rabbit, Apu2, millipore), anti-ubiquitin K63-
specific (mouse, HWA4C4, millipore), anti-ubiquitin (mouse, Enzo), anti-pSTAT1(Y701) 
(Rabbit, Cell Signaling), anti-pSTAT2(Y689)(rabbit, Upstate), anti-STAT2 (Rabbit, Santa Cruz). 
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Immunoblots were developed with the following secondary antibodies: Anti-rabbit IgG-HRP 
conjugated antibody and anti-mouse IgG-HRP from sheep (GE Healthcare; England). The 
proteins were visualized by an enhanced chemiluminescence reagent (Pierce). 
 
TRIM6 knockdown in vivo using PPMOs 
The peptide-conjugated phosphorodiamidate morpholino oligomers (PPMO) were produced by 
previously published methods (Abes et al., 2006). The TRIM6-targeting PMO sequence was: 
AAGCTTAGGACCGACCTGGTACTCC and was designed to specifically target the exon2-
intron 2 junction of TRIM6 pre-mRNA, in an effort to interfere with splicing of pre-mRNA. The 
non-targeting PMO control sequence (NC-705) was: CCTCTTACCTCAGTTACAATTTATA, 
which has no perfect homology to mouse or influenza viral sequences. TRIM6 PPMO is designed 
to remove exon 2, and PPMO efficacy was assessed by RT-qPCR using primers designed to 
amplify the exon2 and exon3 region (primer sequences located in table in supplementary 
information). TRIM6-silencing by PPMO was also assessed by immunoblots. Immunoblots from 
the experiments with PPMO treated mice were quantified using ImageJ (National Institutes of 
Health). In brief, the entire surface from each blot presented in the figures was scanned, with 
lanes (indicated) based on the automatic detection of the software, and the signal then quantified 
within each set lane. The quantified values were normalized to the lowest value within each 
individual blot (arbitrarily set to 1).  
 
RT-qPCR analysis 
Total RNA was isolated using RNeasy kit (Qiagen) and subjected to DNAse digestion with Turbo 
DNase (Ambion). Reverse transcription was performed using the high capacity cDNA reverse 
transcription kit (Applied Biosystems). Real-time qPCR was performed in 384-well plates in 
triplicate using SYBR green I master mix (Roche) in a Roche LightCycler 480. Relative mRNA 
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values were calculated using the ΔΔCt method (Livak and Schmittgen, 2001) using 18S rRNA as 
internal control for human cells or β-actin for mouse cells, and plotted as relative values or fold 
change by normalizing to mock-control samples. 
The PCR primers used were: 
 
RT-qPCR primers 
  
Target Primer sequence 
 hTRIM6 Fwd: 5'-GGGGTATGCAGCAATTCACT-3' 
  Rev: 5'-ACCCAATCACCCAGTATCCA-3' 
 hTRIM1 Fwd: 5'-CCACACCCCAGAGAGGTTTA-3' 
  Rev: 5'-TATTTCCTGCTGCCCCATAG-3' 
 hTRIM5α Fwd: 5'-AGCAATGAGCTGCAAAACCT-3' 
  Rev: 5'-GCTGCACCATCTCAGTTTCA-3' 
 hTRIM25 Fwd: 5'-CGGATGACTGCAAACAGAAA-3' 
  Rev: 5'-TCCTTGTCGAGGTGGTCTCT-3' 
 hTRIM13 Fwd: 5'-CAACGGATGGCCTTTAACAT-3' 
  Rev: 5'-GGCTTGCAGGCAAATTAGAG-3' 
 Influenza-M1  Fwd: 5'-AGATGAGTCTTCTAACCGAGTCG-3' 
 Rev: 5'-TGCAAAAACATCTTCAAGTCTCT-3' 
 hRIG-I Fwd: 5'- GGCATGTTACACAGCTGACG-3' 
  Rev: 5'- TGCAATATCCTCCACCACAA-3' 
 hMxA Fwd: 5'- GTGGCTGAGAACAACCTGTG -3' 
  Rev: 5'- GGCATCTGGTCACGATCCC -3' 
 hOAS1 Fwd: 5'- GATCTCAGAAATACCCCAGCCA-3' 
  Rev: 5'- AGCTACCTCGGAAGCACCTT-3' 
 hSTAT1 Fwd: 5'- ACAGCAGAGCGCCTGTATTG-3' 
  Rev: 5'- CAGCTGATCCAAGCAAGCAT-3' 
 18S rRNA Fwd: 5'-GTAACCCGTTGAACCCCATT-3' 
  Rev: 5'-CCATCCAATCGGTAGTAGCG-3' 
 hIFNβ Fwd: 5'-TCTGGCACAACAGGTAGTAGGC-3' 
  Rev: 5'-GAGAAGCACAACAGGAGAGCAA-3' 
 hTNFα  Fwd: 5'-AGTGAAGTGCTGGCAACCAC-3' 
 Rev: 5'-GAGGAAGGCCTAAGGTCCAC-3' 
 hISG15 Fwd: 5'-TCCTGGTGAGGAATAACAAGGG-3' 
  Rev: 5'-GTCAGCCAGAACAGGTCGTC-3' 
 hISG54 Fwd: 5'-ATGTGCAACCTACTGGCCTAT-3' 
  Rev: 5'-TGAGAGTCGGCCCATGTGATA-3' 
 mActin Fwd: 5'-CGGTTCCGATGCCCTGAGGCTCTT-3' 
 Rev: 5'-CGTCACACTTCATGATGGAATTGA-3' 
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 mIFNβ Fwd: 5'-CAGCTCCAAGAAAGGACGAAC-3' 
  Rev: 5'-GGCAGTGTAACTCTTCTGCAT-3' 
  mADAR1 Fwd: 5'-GGAAAGGCAAGGCGATGTCTA-3' 
 Rev: 5'-GCTTCTTGTCCGTCAAGTACC-3' 
mTRIM6 Fwd: 5’-CTCTTTTGCAAGGAGGATGG-3’ 
 Rev: 5’-CAGGCTCCACCTGACTCTTC-3’ 
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